A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

Experimental Hematology

Volumn 27, Issue 12, 1999, Pages 1724-1734

  Molineux, Graham ^a   Kinstler, Olaf ^a   Briddell, Bob ^a   Hartley, Cynthia ^a   McElroy, Patricia ^a   Kerzic, Patrick ^a   Sutherland, Weston ^a   Stoney, Greg ^a   Kern, Brent ^a   Fletcher, Frederick A ^a   Cohen, Art ^a   Korach, Elliot ^a   Ulich, Tom ^a   McNiece, Ian ^b   Lockbaum, Pamela ^a   Miller Messana, Mary Ann ^a   Gardner, Sheila ^a   Hunt, Thomas ^c   Schwab, Gisela ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c PPD Pharmaco   (United States)

Author keywords

Filgrastim SD 01; Neutropenia; PBPC mobilization

Indexed keywords

CD34 ANTIGEN; FILGRASTIM SD/01; FLUOROURACIL; MACROGOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL ISOLATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MICE;

EID: 0032745325     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00112-5     Document Type: Article

References (29)

1. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907.
2. Bronchud M.H., Scarffe J.H., Thatcher N., Crowther D., Souza L.M., Alton N.K., Testa N.G., Dexter T.M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 56:1987;809.
3. Ulich T.R., del Castillo J., Souza L. Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol. 133:1988;630.
4. Tanaka H., Kaneko T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies. Drug Metab Dispos. 19:1991;200.
5. nd edition:1998;51 Marcel Dekker, New York.
6. Tanaka H., Satake-Ishikawa R., Ishikawa M., Matsuki S., Asano K. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to poly(ethylene glycol) in rats. Cancer Res. 51:1991;3710.
7. Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins.
8. nd edition. New York: Marcel Dekker.
9. Molineux G., Pojda Z., Dexter T.M. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood. 75:1990;563.
10. Welte K., Bonilla M.A., Gillio A.P., Gabrilove J.L., O'Reilly R.J., Souza L.M. Recombinant human granulocyte-colony stimulating factor. in vivo effects on myelopoiesis in primates Behring Inst Mitt. 83:1988;102.
11. Molineux G., Hartley C., McCrea C., McElroy T., McNiece I.K. Continuous subcutaneous infusion of hematopoietic growth factors in mice. Exper Hematol. 23:1995;880.
12. Schwab G., Roskos L., Molineux G., Briddell R., Yang B.B., Cheung E., Miller-Messana M., Lockbaum P., Gardner S., Hunt T. A phase I study of sustained-duration filgrastim in normal volunteers. Exper Hematol. 26:1998;709.
13. Roskos L., Yang B., Schwab G., Lockbaum P., Molineux G., Khoo K., Hunt T., Cheung E.N. A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers. Clin Pharmacol Ther. 65:1999;196.
14. Cheung E.N., Cosenza M., Lopez O., Hayashi M., Wariner G., Roskos L.K. Modelling of r-metHuG-CSF-SD/01 (SD/01) mediated granulopoiesis in normal animals with mathematical extrapolation to neutropenic settings. Blood. 92(Suppl 1):1998;379A.
15. Roskos L.K., Yank B., Schwab G., Lockbaum P., Molineux G., Johnston E., Crawford J., Khoo K., Cheung E.N. Cytokinetic model of rmethHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the and the "self-regulation" of SD/01 elimination in non-small cell lung cancer (NSCLC). Blood. 92(Suppl):1998;507A.
16. Mast J., Salvesen G., Schnebli H.P., Pizzo S.V. Evaluation of the rapid plasma elimination of recombinant alpha1-proteinase. synthesis of poly(ethylene glycol) conjugates with improved therapeutic potential J Lab Clin Med. 116:1990;58.
17. Tanaka H., Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 50:1990;6615.
18. Molineux G., Hartley C., McElroy P., McCrea C., McNiece I.K. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood. 88:1996;366.
19. Molineux G., Hartley C., McElroy P., McCrea C., Kerzic P., McNiece I. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients. Stem Cells. 15:1997;43.
20. de Haan G., Engel C., Dontje B., Nijhof W., Loeffler M. Mutual inhibition of murine erythropoiesis and granulopoiesis during combined erythropoietin, granulocyte colony-stimulating factor, and stem cell factor administration. in vivo interactions and dose-response surfaces Blood. 84:1994;4157.
21. Molineux G., Hartley C., McElroy P., McNiece I. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients. Stem Cells. 15:1997;1.
22. Molineux G., Poida Z., Hampson I.N., Lord B.I., Dexter T.M. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 76:1990;2153.
23. Lane T.A., Ho A.D., Bashey A., Peterson S., Young D., Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transplantation. 39:1999;39.
24. Baumann I., Swindell R., Van Hoeff M.E., Dexter T.M., de Wynter E., Lange C., Luft T., Howell A., Testa N.G. Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. Ann Oncol. 7:1996;1051.
25. Lord B.I., Testa N.G., Bretti S., Chang J., Demuynck H., Coutinho L., de Campos E., Fitzsimmons L., Scarffe J.H. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination. Int J Cancer. 59:1994;483.
26. Lord B.I., Molineux G., Pojda Z., Souza L.M., Mermod J.J., Dexter T.M. Myeloid cell kinetics in mice treated with recombinant interleukin-3,granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood. 77:1991;2154.
27. Capdeville R., Xu Z.-X., Faugeas O., Schulz R., Oberling F., Platzer E. A single injection of RO 25-8315, a long-acting pegylated G-CSF mutein, is safe and effective in mobilizing peripheral blood progenitor cells (PBPC) in healthy volunteers. A clinical pharmacology phase I study. Bone Marrow Transplant. 19(Suppl 1):1997;S12.
28. Xu Z.-X., Capdeville R., Faugeas O., Oberling F., Platzer E. Safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of a long-acting (5-7 days), chemically modified G-CSF mutein (Ro 25-8315) to healthy subjects. Proc ASCO. 16:1997;87a.
29. Farese A.M., Roskos L., Cheung E., Stead R.B., Yin S.M., Macvittie T.J. A single administration of r-metHuG-CSF-SD/01 (SD/01) significantly improves neutrophil recovery following autologous bone marrow transplantation. Blood. 92(Suppl.):1998;112A.